# T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

> **NCT03531736** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Myeloid Diseases

## Interventions

- **DRUG:** Antithymocyte globulin (Rabbit)
- **DRUG:** fludarabine
- **RADIATION:** total body irradiation
- **DRUG:** cyclophosphamide
- **DRUG:** Rituxan
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT03531736
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-09
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531736, "T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03531736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*